Applying the Latest Evidence and NCCN Guideline Recommendations in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Expert faculty review current paradigms and emerging data in treating CLL/SLL with a commentary and downloadable slideset from a satellite symposium.

Share

Program Content

Activities

Frontline Therapy for CLL
Optimal Selection of Therapy for Treatment-Naive CLL
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 06, 2023

View Activity
Treating R/R CLL
Considerations in Selecting Therapy for Previously Treated CLL
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 06, 2023

View Activity
Treating Double-Refractory CLL
Novel Strategies for Treating Double-Refractory CLL
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 07, 2023

View Activity

Activities

CLL Challenges
Key Challenges in Managing Patients With CLL
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: November 15, 2023

View Activity

Faculty

cover img faculity

Danielle Brander, MD

Assistant Professor of Medicine
Division of Hematologic Malignancies and Cellular Therapy
Duke Cancer Institute
Durham, North Carolina

cover img faculity

Brian Hill, MD, PhD

Director, Lymphoid Malignancies Program
Staff Physician, Department of Hematology and Medical Oncology
Taussig Cancer Institute
Cleveland Clinic
Cleveland, Ohio

cover img faculity

Deborah Stephens, DO

Associate Professor
Director of the CLL Program
Lineberger Comprehensive Cancer Center
University of North Carolina
Chapel Hill, North Carolina

Provided by

ProCE Banner

Provided by the National Comprehensive Cancer Network (NCCN) in partnership with Clinical Care Options, LLC.

Supporters

Supported by educational grants from AstraZeneca, BeiGene, Ltd., and Lilly.

AstraZeneca

BeiGene Ltd

Lilly

Partners

Clinical Care Options, LLC

ProCE Banner